New drug combinations for advanced bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or spread bladder cancer that can't be removed by surgery.
- You haven't had any previous treatment for advanced bladder cancer (though earlier treatments for early-stage cancer may be okay).
- You must provide a sample of your tumor from a recent biopsy or one stored from a prior procedure.
- You cannot have certain eye conditions like severe dry eye or active cornea problems.
- You must not have serious active heart or blood vessel disease, uncontrolled diabetes, or a history of immune system disease that required treatment in the last 2 years.
- You cannot have active cancer spread to the brain or lining of the brain, or other cancers requiring treatment in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well pembrolizumab and an antibody-drug medicine (EV) given with bladder radiation work for non-metastatic bladder cancer that is mostly urothelial. It may help some people control the cancer without it spreading to other organs.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This trial tests a new study drug (GB-4362) when added to the usual combination of enfortumab vedotin and pembrolizumab for advanced bladder cancer. It is for people who are about to start this standard treatment and have not had these drugs before.
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) given before surgery can help patients with muscle-invasive bladder cancer or upper-tract urothelial cancer. The goal is to shrink tumors and improve outcomes before surgery removes the cancer.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.